Premium
Five‐year experience in the treatment of focal movement disorders with low‐dose dysport TM botulinum toxin
Author(s) -
Van Den Bergh P.,
Francart J.,
Mourin S.,
Kollmann P.,
Laterre E. C.
Publication year - 1995
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.880180708
Subject(s) - blepharospasm , cervical dystonia , medicine , dystonia , hemifacial spasm , botulinum toxin , focal dystonia , dysphagia , dermatology , anesthesia , surgery , facial nerve , psychiatry
We report the results of botulinum toxin type A (Dysport TM , Porton Products, UK) treatment over 5 years in 107 patients with blepharospasm, Meige's syndrome, oromandibular dystonia, hemifacial spasm, cervical dystonia, and writer's cramp. Electromyography was used to localize dystonic muscles and guide Dysport TM injections in Meige's syndrome, oromandibular dystonia, cervical dystonia, and writer's cramp. All but 2 Meige's syndrome and 2 writer's cramp patients responded to treatment. Improvement was dramatic in blepharospasm (79%) and hemifacial spasm (90%); pronounced in cervical dystonia (74%); and moderate in Meige's syndrome (53%), oromandibular dystonia (57%), and writer's cramp (34%). Although Dysport TM doses were 50–75% lower than usually reported, response and improvement rates as well as relapse intervals were similar to those of others. To treat cervical dystonia relapses, only 50% of the initial dose was required for continued optimal relief of symptoms. Low‐dose Dysport TM was associated with a very low incidence of dysphagia in cervical dystonia. © 1995 John Wiley & Sons, Inc.